Phase 1 Vasculitis Trial, Recruiting NCT06056921 Sponsor: Chongqing Precision Biotech Co., Ltd Condition: Vasculitis
Back to Vasculitis

Phase 1 Vasculitis Trial, Recruiting

NCT06056921
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with one of the following conditions: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome, Systemic Scleroderma, Dermatomyositis (with a specific positive antibody test result), or a type of blood vessel inflammation called ANCA-associated vasculitis (including GPA, MPA, or EGPA) — diagnosed using specific medical standards
  • Your disease is considered active enough to meet specific scoring thresholds set for each condition (confirm with trial site for the exact score required for your condition)
  • You are generally well enough to carry out light activity or normal daily tasks (rated 0 or 1 on a standard health performance scale)
  • Your blood counts meet minimum levels — for example, haemoglobin of at least 60g/L and platelets of at least 30×10⁹/L
  • Your heart is pumping well enough, with no major abnormalities on a heart tracing (ECG)
  • Your kidneys are working at a sufficient level (eGFR of at least 30 mL/min/1.73m²)
  • Your liver test results are within acceptable ranges
  • Your lungs are functioning above minimum required levels on breathing tests
  • You are able to have blood taken or cells collected without major complications
  • If you could become pregnant, you have a negative pregnancy test and agree to use effective contraception during the trial and for one year after receiving the treatment
  • You (or your guardian) fully understand the trial and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have previously received a type of treatment called CAR T cell therapy
  • You have serious heart, liver, lung, blood, hormonal, or other organ problems where the risks of joining the trial are considered greater than the possible benefits (as judged by the medical team)
  • You have an active or uncontrolled infection that needs treatment throughout the body within one week before assessment
  • You have previously had a stem cell transplant or organ transplant (except cornea or hair transplants), or have had a significant transplant rejection reaction within two weeks before assessment
  • You have active Hepatitis B, Hepatitis C, HIV, syphilis, or an active cytomegalovirus (CMV) infection based on blood tests
  • You have received a live vaccine within four weeks before assessment
  • You have a positive pregnancy test
  • You have or have had a cancer diagnosis, with some exceptions such as certain fully treated skin cancers, early-stage cervical cancer, or certain prostate or breast cancers that have been treated with surgery (confirm with trial site)
  • You have taken part in another clinical trial within the three months before assessment
  • The medical team considers participation to be unsuitable for you for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Liyun Zhang, M.D, Shanxi Bethune Hospital

Phone: 13834547708

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chongqing Precision Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
31 August 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse events after CD19 CAR-T cells infusion [Safety and Tolerability]; Obtain the maximum tolerated dose of CD19 CAR-T cells[Safety and Tolerability]; Efficacy of CAR-T cell preparations in Refractory systemic lupus erythematosus [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory Systemic scleroderma [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory Sjogren's syndrome [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory dermatomyositis [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory The antineutrophil cytoplasmic...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov